Ignite Creation Date:
2024-10-26 @ 3:36 PM
Last Modification Date:
2024-10-26 @ 3:36 PM
Study NCT ID:
NCT06529549
Status:
RECRUITING
Last Update Posted:
None
First Post:
2024-07-26
Brief Title:
Efficacy and Safety of Organoid-Based Drug Sensitivity Screening to Guide the Treatment of mCRPC Patients Progressed After First-line Treatment
Sponsor:
None
Organization:
None
Study Overview
Official Title:
A Prospective Open-label Single-arm Study on the Efficacy and Safety of Organoid-Based Drug Sensitivity Screening to Guide the Treatment of mCRPC Patients With Bone Metastasis Progressed After First-line Treatment
Status:
RECRUITING
Status Verified Date:
2024-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This observational study aims to learn about the effects and safety of organoid-based drug sensitivity screening in mCRPC patients with bone metastases that progressed after first-line treatment The main question it seeks to answer is
Do doctors choose treatment agents based on organoid-based drug sensitivity screening results for mCRPC patients resulting in a better response
Participants already took bone metastasis biopsies for genetic testing based on current clinical guidelines This study only takes residual tissue from biopsies for organoid culture
Do doctors choose treatment agents based on organoid-based drug sensitivity screening results for mCRPC patients resulting in a better response
Participants already took bone metastasis biopsies for genetic testing based on current clinical guidelines This study only takes residual tissue from biopsies for organoid culture
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None